SMARCA4/2 Inhibitor for POU2F3-Positive SCLC

Clinical trial NCT07551635 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07551635
Sponsor: Dana-Farber Cancer Institute
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Small Cell Lung Cancer

Start date: 2026-09-04
Primary completion: 2028-01-31
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.